Sign in

Research summary ·

Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This was a review of studies of lenvatinib plus pembrolizumab in endometrial cancer. Doctors sometimes start lenvatinib below 20 mg for people who may tolerate it poorly. The team compared lower starting doses with 20 mg. They used observational studies. 10 studies with 1,000 patients were included.

What they found

A subset of cohorts, with 703 patients, fed the main comparison. Response was similar for lower and full starting doses. The pooled risk ratio was 0.97. Disease control was also similar, at 0.96. The risk ratio for later dose reduction was 0.66. Other results were imprecise. Every result had a serious risk of bias. Certainty of the evidence was very low for each pooled result.

What it means for patients

The authors said observational data do not show a lower start keeps the drug working. They also do not show better tolerance. They said prospective studies are needed before a lower start can be broadly backed.

Why it is not certain yet

All results had serious risk of bias. Certainty of evidence was very low. The studies only observed patients. Some results could not be pooled.

Source

Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence.

PubMed · PMID 42964024

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Endometrial cancer publications